bio stat

140  |  Reprod Med Biol. 2019;18:140–150.wileyonlinelibrary.com/journal/rmb

1   |   I N T R O D U C T I O N

In 1942, Klinefelter and Albright reported that nine men had a “Syndrome characterized by gynecomastia, aspermatogenesis without Leydigism and increased excretion of follicle‐stimulating hormone”.1 Karyotype analysis elucidated that this syndrome was caused by an extra X chromosome (XXY). The classic form (nonmo‐ saic type) of Klinefelter syndrome (KS) is observed in one per 660 births, with up to 3%‐4% occurring in infertile men and 10%‐12% occurring in nonobstructive azoospermia (NOA). A study on the KS

prevalence in Japan found a lower prevalence at 60 per 100 000,2 indicating the presence of racial differences. KS is the most common sex chromosome abnormality associated with male infertility,3,4 and men with KS have been shown to be potentially fertile by using a testicular sperm and intracytoplasmic sperm injection (ICSI) proto‐ col.6 Approximately 85% of KS cases are due to a single aberrant X chromosome (47,XXY), whereas the remaining 15% display multiple aneuploidies (48,XXXY; 48,XXYY; 49,XXXXY), causing the devel‐ opment of more severe phenotypes, which are usually diagnosed during prenatal and infantile periods as abnormalities of the external

Received: 3 October 2018  |  Revised: 7 November 2018  |  Accepted: 11 November 2018 DOI: 10.1002/rmb2.12261

R E V I E W A R T I C L E

Klinefelter syndrome: From pediatrics to geriatrics

Koji Shiraishi  | Hideyasu Matsuyama

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2018 The Authors. Reproductive Medicine and Biology published by John Wiley & Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.

Department of Urology, Yamaguchi University School of Medicine, Ube, Japan

Correspondence Koji Shiraishi, Department of Urology, Yamaguchi University School of Medicine, Ube, Japan. Email: shirak@yamaguchi‐u.ac.jp

Abstract Background: Klinefelter syndrome (KS) is one of the major causes of nonobstructive azoospermia (NOA). Microdissection testicular sperm extraction (micro‐TESE) is often performed to retrieve sperm. Infertility specialists have to care for KS patients on a lifelong basis. Methods: Based on a literature review and our own experience, male infertility treat‐ ment and KS pathophysiology were considered on a lifelong basis. Main findings: Patients diagnosed early often have an increased number of aberrant X chromosomes. Cryptorchidism and hypospadias are often found, and surgical cor‐ rection is required. Cryopreservation of testicular sperm during adolescence is an issue of debate because the sperm retrieval rate (SRR) in KS patients decreases with age. The SRR in adult KS patients is higher than that in other patients with NOA; however, low testosterone levels after micro‐TESE will lower the general health and quality of life. KS men face a number of comorbidities, such as malignancies, meta‐ bolic syndrome, diabetes, cardiovascular disease, bone disease, and immune dis‐ eases, which ultimately results in increased mortality rates. Conclusion: A deeper understanding of the pathophysiology of KS and the histories of KS patients before they seek infertility treatment, during which discussions with multidisciplinary teams are sometimes needed, will help to properly treat these patients.

K E Y W O R D S

comorbidity, Klinefelter syndrome, microdissection testicular sperm extraction, nonobstructive azoospermia, pediatrics, testosterone

     |  141SHIRAISHI And MATSUYAMA

genitalia.7 A structurally abnormal X chromosome (eg, 47,iXq,Y) or mosaicisms (eg, 47,XXY/46,XY) are also included in KS. The origin of the aberrant X chromosome in KS, of either paternal or maternal origin, and how the presence of a supernumerary X chromosome causes the phenotype and morbidity in KS are not fully understood.

The multiple aneuploidies causing the abnormalities of external genitalia and children with KS with severe intellectual and behav‐ ioral problems are relatively rare compared with other cases of male infertility, usually NOA. These are symptoms often present among men with KS, and in most of the cases, lead to its diagnosis during the workup for infertility. Less than 10% of these patients are di‐ agnosed before puberty.3 On the other hand, we should not forget that KS is also responsible for general comorbidities related to met‐ abolic and psychological disorders and risks of specific malignancies, which, in part, are caused by low testosterone in KS patients. As microdissection testicular sperm extraction (micro‐TESE) has been shown to be an ideal sperm retrieval method8 used by many urolo‐ gists and, in Japan, gynecologists, the chances of low‐testosterone‐ related symptoms and comorbidities are increasing. The testicular size is significantly smaller and serum testosterone levels are lower in KS patients compared to those in other NOA cases; thus, a post‐ micro‐TESE decline in testosterone is enhanced in KS patients.9 Unfortunately, we often see many KS patients who claim to have impaired sexual function, general fatigue, and comorbidities after micro‐TESE, and they are not properly followed up after micro‐TESE irrespective of the results of sperm retrieval. Diagnosing KS should be the beginning of a strict follow‐up of general health; however, reproductive medicine has caused new and severely low levels of testosterone in men with KS in the era of assisted reproductive tech‐ nologies (ART).

Data related to infertility treatment are apt to be focused on the sperm retrieval of KS. The purposes of this review are to understand the background pathophysiology of KS patients, including how they grew up, which symptoms occurred before they were treated for infertility, what information is available after their infertility treat‐ ment, and finally how they should be managed for lifelong basis.

2   |   K S A N D I N F E R T I L I T Y T R E AT M E N T

For a long time, KS was considered to be an absolute infertility condi‐ tion once diagnosed. In 1996, Tournaye et al10 reported a successful testicular sperm retrieval by conventional TESE in men with KS. One year later, Palermo et al6 reported the first pregnancy and live birth resulting from a KS father after TESE/ICSI. A recent review reported by Majzoub et al11 indicated that publications from many different centers documented sperm retrieval rates (SRRs) in KS adults of ap‐ proximately 50%‐70%, which are higher than those of general NOA cases, and reported excellent pregnancy rates and healthy 46,XY or 46,XX offspring. A recent meta‐analysis has shown an overall SRR of approximately 40%, ranging from 1% to 50%, in both conventional TESE and micro‐TESE.12 These results indicate that micro‐TESE, but not conventional TESE, is an ideal method to retrieve sperm from

men with KS. A survey conducted on Dutch patients reported that the majority of KS patients and their partners would like to have a positive attitude toward TESE/ICSI to conceive a child.13

The age at micro‐TESE is the only parameter to predict success‐ ful sperm retrieval. Okada et al14 reported that the SRR was 81% in patients 25‐29 years of age, 73% in patients 30‐34 years of age, 25% in patients 35‐39 years of age, and 22% in men 40‐44 years of age, and proposed that micro‐TESE should be performed before 35 years of age in men with KS. Data from the Cornell group showed that the SRR in men with KS was 71% in the 22‐ to 30‐year age‐group, 86% in the 31‐ to 35‐year age‐group, and 50% in the 36‐ to 50‐year age‐group. In fact, age affects the SRR, but the data are not bleak.

The hormonal pattern and testicular volume have been advo‐ cated as possible prognostic factors for successful SRR in KS pa‐ tients.5,15,16 Rohayem et al18 reported that the combination of total serum testosterone above 7.5 nmol/L and LH levels below 17.5 U/L resulted in higher retrieval rates of spermatozoa by micro‐TESE in both adolescents and adults with KS. Similar results were more re‐ cently reported by Cissen et al19 Interestingly, Rohayem et al18 did not document any clinical difference in nonmosaic KS patients with or without spermatozoa in their seminal fluid. The lack of prognostic value of the FSH levels might be related to the low inhibin B levels (which is almost undetectable during early puberty) in all patients with KS, which does not allow for the negative feedback of FSH secretion.20

It should be recognized that postoperative testicular damage leading to a decrease in testicular function has been described as a complication of micro‐TESE. The transient but statistically signifi‐ cant decrease in testosterone levels indicates that men are at risk of developing hypogonadism after micro‐TESE, but there is insufficient evidence for whether patients actually experience clinical symptoms in the case of decreased serum testosterone levels. One apparent parameter to predict post‐micro‐TESE hypogonadism is KS,9 and a recent meta‐analysis has shown that men with KS and men with NOA had the strongest decreases in total testosterone levels at 6 months after TESE.21 The largest disaster regarding this issue is that a ma‐ jority of men with KS are not properly followed up after micro‐TESE, which will be addressed in another section in this review.

3   |   P R E N ATA L , I N FA N T I L E , A N D P E D I AT R I C P E R I O D S

The opportunity for physicians to diagnose and manage KS may occur even during the prenatal period, as the diagnosis is sometimes established by prenatal genetic information. The recent develop‐ ment of noninvasive prenatal screening is anticipated to increase the number of couples seeking counseling; however, a discussion on whether to abort has never occurred in KS cases.

Studies in KS infants have found that the postnataltempo‐ rary surge in gonadotropins (“mini‐puberty”) may be accompanied by low testosterone levels22,23 or normal testosterone levels.24,25 Simultaneously, FSH levels increase at 2‐3 months after birth,

142  |     SHIRAISHI And MATSUYAMA

followed by a subsequent rapid decline.25 This early exposure of an‐ drogens is severely disturbed with an increase in the number of X chromosomes. Genital anomalies (micropenis, undescended testis, bifid scrotum, and hypospadia) might present at birth, but whether they are due to the effects of supernumerary X chromosome(s) or androgen deficiency during the fetal period remains undetermined. Figure 1 shows a case of a KS baby with 49,XXXXY that was referred to us for the evaluation of sex development disorders. He under‐ went bilateral orchiopexy and two‐stage hypospadia repair, and he can now void at standing position. On the other hand, individuals with mosaic KS tend to present with milder symptoms.

Basically, testosterone‐related symptoms do not occur during infancy or early pediatric periods. Signs and symptoms appearing during this period, such as longer legs, disturbance of speech and cognition,adaptation problems, attention deficits, and social skill impairments,26,27 have been attributed to the genetic abnormality rather than to hypogonadism. As a result, men with KS are prone to learning difficulties, and their academic and professional status achievements are reported to be inferior to those without KS28; however, this finding has not been fully investigated, and men with KS who visit our infertility clinic, of course they are only limited cases of KS, are always highly educated and talented. The management of children with KS warrants the collaboration of a multidisciplinary team consisting of pediatricians as well as behavioral specialists to ameliorate the developmental defects in early life.29 In addition, an echocardiographic study should be performed to reveal congenital cardiovascular abnormalities.30

Although multidisciplinary treatment for each child with KS should be administered and testosterone may not play a major role in the treatment of KS during this period, there are some anticipated benefits of testosterone replacement therapy (TRT) on the improve‐ ment of the energy level, attention span, mood, and cardiac health of young KS patients.31,32 Recently, two reports have indicated that early TRT may be beneficial for developmental and behavioral issues in boys with KS without serious adverse effects.33,34 However, there is concern that TRT might cause obstructive sleep apnea and venous thromboembolism.35,36 In addition, there is evidence that TRT in boys with KS is not as effective as that observed in males with a nor‐ mal karyotype, at least regarding body proportions and bone min‐ eral density (BMD).37,38 Studies that apply population‐based genetic screening should be performed to investigate a proper evaluation

of the costs and benefits of such an approach in KS patients.39 Randomized controlled trials are also needed to evaluate the efficacy of TRT on different aspects of the symptoms, to determine optimal dose regimens and, most importantly, to prevent the impairment of spermatogenesis or to stimulate future spermatogenesis in boys with KS.40 In this situation, psychological aspects regarding their future reproductive function should be taken into consideration to avoid negative impacts on reproductive health, and follow‐up should be performed by a specialized team consisting of pediatricians, adult endocrinologists/andrologists, and psychologists during the transi‐ tion from pediatric and adolescent periods to adulthood.

4   |   A D O L E S C E N T P E R I O D

Although the onset of puberty in KS patients occurs at the same time as that in normal boys, hypogonadism remains silent until pu‐ bertal onset because testosterone levels are usually sufficient for satisfactory development of the body and genitalia.41,42 Additionally, the severity of low‐testosterone‐related symptoms is mild in KS pa‐ tients during the adolescent period, unlike in male hypogonadotropic hypogonadism. Furthermore, the negative feedback elevation of LH activates aromatase, resulting in an increase in estradiol, which may contribute to the development of gynecomastia.43 At puberty, only a few patients notice overt hypogonadism signs, such as poor muscle development, a short penis, and a lack of or sparse pubic, axillary, and facial hair. Low‐to‐normal testosterone levels contribute to the development of tall stature and disturb the ratio between the upper and lower skeletal segments.44 On the other hand, Bojesen et al re‐ ported that 65%‐85% of KS patients present overt hypogonadism after the age of 25,45 and this number might differ among countries and according to the circumstances surrounding KS patients.

Along with LH, FSH is increased via the negative feedback mech‐ anism of testosterone, estradiol, and inhibin B, whichultimately cause the hypergonadotropic levels observed in adult KS patients.46 Additionally, we suspect that some disturbances in testicular devel‐ opment occur during this period. The testes of KS adolescents can develop to a volume of 6 mL due to the proliferation and maturation of Sertoli and Leydig cells,47 which is considered to be normal ini‐ tial testicular development. Rising intratesticular testosterone levels are subsequently followed by an accelerating decline in germ cells,

F I G U R E 1   Photographs of proximal hypospadias and penoscrotal disposition in a newborn with a 49,XXXXY karyotype are shown (A). The scrotum is raised, and a small penis is observed (B). This patient was managed with bilateral orchiopexy and a 2‐stage hypospadias repair with a simultaneous correction of a penoscrotal transposition repair

     |  143SHIRAISHI And MATSUYAMA

hyalinization of the tubules, degeneration of Sertoli cells, and hyper‐ plasia of Leydig cells,47 resulting in the loss of testicular volume and a decrease in serum testosterone levels. It is still unclear why the rise in serum or intratesticular testosterone during puberty is associated with accelerated destruction of the seminiferous tubules during this period.48 Lue et al49 suggested that germ cell defects occurred sec‐ ondary to a defect in spermatogonial migration during the postnatal period and not the prenatal period in XXY mice. On the other hand, normal spermatogenesis in KS can potentially be explained by the following three mechanisms: (a) Occult intratesticular mosaicism in which 46,XY spermatogonia are able to differentiate normally into mature sperm50; (b) Spermatogenesis arising from 47,XXY sper‐ matogonia. It has previously been demonstrated that 47,XXY sper‐ matogonia and spermatocytes are able to enter the spermatogenic process, leading to the formation of mature sperm51; and (c) Active repair of testicular stem cell renewal via the silencing or loss of the extra X chromosomes.52 This phenomenon causes the presence of ejaculate sperm during the adolescent period in some KS patients, which leads to the hypothesis that SRR by TESE might be superior during the adolescent period rather than in the adult period to pre‐ serve future fertility potential.

5   |   I S T E S E D U R I N G A D O L E S C E N C E E F F E C T I V E I N K S PAT I E N T S ?

Limited data suggest that sperm production in men with KS, as de‐ termined by the results of TESE, is rapidly impaired after a certain age (approximately 35 years of age), and it might be better to retrieve sperm as soon as the diagnosis is made. This suggestion was gener‐ ated from data reported by Okada et al.14 In their study, the SRR in 25 patients >35 years of age was only 23%. On the other hand, data from Cornell University showed that the SRR in men with KS was 71% in the 22‐ to 30‐year age‐group, 86% in the 31‐ to 35‐year age‐ group, and 50% in the 36‐ to 50‐year age‐group. In our experience, the SRR in 84 men with KS was 61% (11/18) in the 21‐ to 30‐year age‐group, 55% (21/38) in the 31‐ to 35‐year age‐group, 52% (14/27) in the 36‐ to 50‐year age‐group, and 100% (1/1) in 52‐year‐old men. Based on these results, spermatogenesis in men with KS declines gradually and not rapidly. Taking these results together with the biological information that progressive hyalinization of seminiferous tubules is observed after puberty in men with KS,47,48 it has been suggested that performing earlier TESE procedures might result in better SRR results.17 A meta‐analysis has shown that successful SRR in KS patients is independent of age.12

Several studies have reported the presence of sperm by ejacula‐ tion in adolescents and young adults with KS,15,53,54 and these sperm should be cryopreserved for future treatment. However, problems arise in KS adolescents who have never performed masturbation or whose semen analysis results in azoospermia. In this situation, TESE is an option for evaluating spermatogenesis and sperm retrieval. In 2001, Damani et al56 first reported the results of TESE in a 15‐year‐ old adolescent to preserve fertility before TRT for the symptoms of

hypogonadism. In 2004, Wikstrom et al47 performed a single‐site testis biopsy for histologic analysis in 14 adolescents with KS, which is the same procedure used for conventional TESE, and reported that no mature sperm were observed in any tissue sections. In this study, a few types of Ap and Ad spermatogonia were found in seven boys aged 10‐12.5 years, whereas no spermatogonia of any type were detected in the other seven boys aged 11.7‐14 years, and they con‐ cluded that diploid germ cells vanished in early puberty in boys with KS.47 In 2012, Gies et al54 reported data from testicular biopsy in seven boys aged 10.2‐15.6 years, and they could not find any mature sperm; however, they could identify spermatogonia upon histologic analysis in four of the boys. In 2013, Rives et al57 published their results in five adolescents with KS who underwent bilateral conven‐ tional TESE and noted that sperm were found in a 16‐year‐old boy, elongated spermatids and spermatocytes were found in a 15.5‐year‐ old boy, and no germ cells were found in the remaining three boys aged 15‐16.5 years. In the same year, Van Saen et al reported that no mature sperm were found in adolescents boys with KS, but 72% (5/7) of the patients, boys with KS from 13 to 16 years of age, pre‐ sented with spermatogonia. The overall number of spermatogonia in the boys with KS was significantly reduced compared with that in normal adolescent boys.58,59

The micro‐TESE procedure performed in adolescent boys with KS was first performed by a Cornell group and reported by Mehta et al in 2013. Ten KS patients aged 14‐22 years underwent micro‐ TESE, and mature sperm were found in seven patients (SRR: 70%).60 A subsequent publication from the same institution showed a 65% retrieval rate in 127 KS adult men, which was the same rate of suc‐ cess for adolescents and adults.61 Plotten et al62 investigated the largest series to date comparing SRRs at the same institution for young KS patients aged 15‐23 years and adult KS patients more than 23 years of age and found SRRs of 52% and 62%, respectively, which were not significantly different. In the same year, Rohayem et al18 reported the results of micro‐TESE in 50 adolescents from 13 to 19 years of age, and the SRR was 38% (19/50). Their result was interesting because the SRR was 10% (1/10) in the subgroup of ado‐ lescents between 11 and 14 years of age, whereas in the adolescents between 15 and 19 years of age, the SRR was much higher at 45% (18/40).18 Most recently, Nahata et al55 reported a 50% SRR in 10 adolescent boys with KS between 15 and 23 years of age and indi‐ cated no distinct pattern or prediction based on the clinical data. The accumulated data from these publications showed that total SRRs by conventional TESE were 30% (15/50) and 42.6% (29/68) by micro‐ TESE, which is summarized in Figure 2. It is clear that micro‐TESE has a substantial advantage for retrieving sperm, but the risks and ben‐ efits of the procedure must be considered. Information related to reproductive outcomes is still lacking; for example, the ICSI results related to using frozen sperm, how many KS patients have successful sperm retrieval, how many KS patients are married, and how many KS patients could have a child born live have not been determined. Experimentally, there are several options for cryopreservation of spermatogenic stem cells from either a testicular cell suspension or testicular tissue. However, there are no reports of inducing haploid

144  |     SHIRAISHI And MATSUYAMA

cells in vitro using 47,XXY spermatogonia. In summary, fertility pres‐ ervation techniques for adolescent boys with KS are still experi‐ mental, and use of the cryopreserved material when the boys reach adulthood cannot be guaranteed.

One dilemma in the management of adolescent KS patients is the negative effect of TRT on spermatogenesis.TRT has previously been reported to have a negative impact on the future fertility of KS patients, as an SRR of 20% was observed in five adults with KS.63 In contrast, Plotton et al62 found no negative influence of TRT on sperm retrieval in 41 KS patients and reported an SRR by micro‐TESE in 9/17 (52.9%) men with previous TRT and a positive TESE in 14/24 (59.1%) men with KS who never had TRT. TRT was stopped 9 months prior to micro‐TESE. Another study included 10 KS adolescents who received continuous topical testosterone replacement and/or an aromatase inhibitor and found mature sperm by micro‐TESE in seven of 10 participants (70%).60 Considering these results together, TRT is unlikely to have a permanent negative impact on spermatogenesis, but larger studies and other medical treatment (eg, gonadotropins, clomiphene, other aromatase inhibitors) are warranted to confirm these findings.

Most importantly, we must consider how patients and their fam‐ ilies feel about fertility preservation, especially in cases in which micro‐TESE needs to be performed. A psychosocial investigation clearly demonstrates a high incidence of negative feelings toward infertility and its effect on overall life satisfaction and well‐being.64 Two other studies have shown that reproductive function is not an

issue of awareness in adolescent boys with KS, whereas their parents and physicians appreciate fertility preservation at a young age.57,65 The influence of a TESE procedure on the psychological health of adolescents with KS has not been investigated, and further studies are warranted.

6   |   P O S T I N F E R T I L I T Y M A N A G E M E N T: D I A G N O S I S O F K S I S A P R O X Y O F G E N E R A L H E A LT H

A 26‐year‐old man with KS was referred to our clinic and com‐ plained of decreased libido and general fatigue. His testicular size was 0.5 mL bilaterally, and his total testosterone concentration was 15 ng/dL. He underwent micro‐TESE at an IVF clinic 6 months prior to visit at our clinic, and his preoperative total testosterone level was 276 ng/dL. Unfortunately, no sperm were found in his testes, and his management was stopped at the clinic. At our hospital, he started TRT every 3 weeks, and his symptoms were dramatically improved. This type of case is not rare but rather very common in our urology department. What are the problems in this case?

In addition to reproductive medicine, many urologists in Japan are engaged in general urology as well as nephrology, hemodialy‐ sis, and renal transplant, which enables a quick start to the manage‐ ment of comorbidities, such as hypertension, diabetes, dyslipidemia, and hyperuricemia, in most men with KS after infertility treatment

F I G U R E 2   The numbers of patients and sperm retrieval rates in adolescents who underwent conventional (A) and micro‐testicular sperm extraction (B) procedures are shown. The closed bar indicates no sperm retrieval, and the open bar indicates successful sperm retrieval

0

5

10

15

20

0

10

20

30

40

9, 10 11, 12 13, 14 15, 16 17-19 years 13, 14 15, 16 17-19 years

N u

m b

er o

f p

at ie

n ts

N u

m b

er o

f p

at ie

n ts

SRR: 0% 0% 14% 21% 65% SRR: 15% 50% 48%

(A) (B) ESET-orciMESET lanoitnevnoC

F I G U R E 3   The symptoms of and strategies for managing Klinefelter syndrome on a lifelong basis and the roles of those who should participate in the management

     |  145SHIRAISHI And MATSUYAMA

(Figure 3). If micro‐TESE is performed at an IVF clinic by either a urologist or gynecologist, patients are recommended to visit the urology/andrology or endocrinology department as soon as possible for follow‐up for an extended period. In other words, micro‐TESE induces new and severely low testosterone levels in recipients. Furthermore, we must make every effort to improve our ability to

diagnose KS. The high frequency of mild KS phenotypes explains, at least in part, why a majority of the patients remain undiagnosed.66 A distinct racial difference in the prevalence of KS and the patterns of symptoms during the pediatric and adolescent periods are still unclear; in our experience, the BMIs of men with KS who visited an infertility clinic are obviously low (approximately 23) compared with

T A B L E 1   Comorbidity of Klinefelter syndrome (KS)

Findings References

Cancer

Extragonadal germ cell tumors Nonseminomatous subtype Nichols (1987)103

Younger than non‐KS

Breast cancer 4‐ to 60‐fold compared with non‐KS Swerdlow et al (2005)94 Brinton (2011)75 Sasco et al (1993)74 Gomez‐Raposo et al (2010)76

Younger than non‐KS

Metabolism

Obesity, metabolic syndrome Abdominal fat is increased Bojesen et al (2006)90 Aksglaede (2008)104 Laaksonen (2014)105 Pasquali et al (2013)38

4‐ to 5‐fold compared with non‐KS

Odds ratio of 2.3 with low testosterone

Effect of TRT on BMI is controversial

Diabetes 8%‐50% in Western countries Takeuchi (1999)106 Lichiardopol (2004)107 Swerdlow et al (2005)94 Bojesen et al (2006)90 Pasquali et al (2013)38

3.9%‐4.1% in Japan

HR of 2.21 for T1D and 3.71 for T2D

Prediabetes is more frequent

No effect of TRT

Cardiovascular disease

Congenital abnormalities Mitral valve prolapse Fricke (1981, 1984)108,109 Pasquali et al (2013)38Diastolic dysfunction

Conduction defects Short QTc interval Jorgensen (2015)93 Liu (2010)110 Lai (2009)111

Atrial fibrillation

Thrombosis Hazard ratio of 3.6 to 5.7 for pulmonary thrombosis Bojesen et al (2006)90 Swerdlow et al (2005)94 Campbell et al (1981)96

Hazard ratio of 6.6 to 7.9 for deep vein thrombosis

Bone disease

Osteoporosis/fracture Decreased bone mineral density Bojesen et al (2006)90 Swerdlow et al (2005)94 Bojesen and Gravholt (2011)68 Ferlin et al (2015)98

Femur fracture

8‐fold increase compared with non‐KS

Low levels of 25‐OH vitamin D

Immunological diseases

Autoimmune diseases 13‐fold increase in systemic lupus erythematosus compared with non‐KS

Scofield (2008)112 El‐Mansoury (2005)113 Sawalha et al (2009)100 Rovensky et al (2010)101 Seminog et al (2015)102

Rheumatic diseases

Addison's disease

Diabetes mellitus type 1

Multiple sclerosis

Acquired hypothyroidism

Sjogren's syndrome

TRT, testosterone replacement therapy.

146  |     SHIRAISHI And MATSUYAMA

those described in data from the United States and Europe (approx‐ imately 24‐30). Investigations regarding the patterns of comorbidity and the TRT treatment regimen for KS patients from Japan and Asian countries are warranted.

Based on data from epidemiological studies, KS is associated with increased morbidity and mortality althoughall the information collected regarding KS is derived from diagnosed cases comprising only approximately 25% of the expected affected number of pa‐ tients.3,66 In other words, the diagnosis of KS at the time of infertility treatment is a special opportunity to evaluate their general health, and patients and medical providers should begin follow‐up and the management of comorbidities. Multidisciplinary management is needed for lifelong follow‐up (Figure 3).

Comorbidities associated with KS, such as metabolic syndrome, diabetes, osteoporosis, and cardiovascular diseases, often appear in adulthood, with many of the patients being of reproductive age; these comorbidities increase with age,67 which is ultimately related to a significant increase in mortality risk. Actually, men with KS re‐ quire more frequent hospitalization, and the life span of KS patients appears to be shorter by approximately 2.1 years compared to that of the general population.68 The main comorbidity associated with in‐ creased mortality risk is the increased prevalence of type 2 diabetes and thrombosis/embolism disorders, both of which are risk factors of cardiovascular events.69 Other conditions increasing the morbid‐ ity of men with KS are osteoporosis and bone fractures as well as the higher prevalence of specific types of cancer and immunological diseases (Table 1). The reason for this impaired mortality is not well understood, and further investigations are needed to clarify whether it is due to the syndrome per se or is mainly a consequence of low testosterone levels. A number of reports show that low testosterone is a biomarker for increased mortality in normal healthy men.70

In addition to the comorbidities mentioned above, the loss of mus‐ cle and a depressed mood due to low testosterone are not directly related to mortality but are associated with a markedly decreased quality of life.71 Of note, from observational studies, some positive effects of TRT in KS have been reported, including decreased fatigue, less irritability, and improved libido, muscle strength, and sleep.72,73 The general consensus indicates that most men with KS should be offered TRT around the time of puberty with a target testosterone level in the high normal range.45 However, no randomized placebo‐ controlled trials have been performed to date to verify this recom‐ mendation, and data on future spermatogenesis remain unknown. As a result, the timing of the initiation and the dose of TRT in KS patients remain topics for further investigation. Specifically, a study on treatment during the pediatric period showed promising results for improving behavior and neurodevelopment,33 and this treatment could have an overall positive effect on social integration during the pediatric and adolescent periods and, presumably, also in adult life.

6.1 | KS and cancer

Breast cancer andgerm cell tumors, especially extragonadal tumors, occur more frequently in KS patients than in the general population

(Table 1). Several meta‐analyses concerning the prevalence of male breast cancer have shown the incidence of breast cancer in KS to be increased 4‐ to 30‐fold compared with that in normal men,74,75 which supports that KS is the strongest independent risk factor for breast cancer in males.76 The mean age of breast cancer onset in KS patients is 58 years,77 which is earlier than that of normal healthy men (67 years of age).78 The early diagnosis of breast cancer requires monthly breast self‐examination and a periodic physical examination by a specialized physician.75 A markedly increased prevalence of germ cell tumors in KS patients has been confirmed in pathology‐ based studies,79 and nonseminomatous tumors are the major patho‐ logical type. Additionally, the diagnosis occurs at a younger age in KS patients than in normal healthy men. A recent Italian consensus80 suggests a biannual chest X‐ray to address the risk of extragonadal germ cell tumors.

On the other hand, the prevalence of prostate cancer and the associated mortality have been reported to be lower in KS patients than in normal healthy men.79,81 The reason for these lower rates may be because the presence of hypogonadism does not stimulate the growth of prostate cancer cells, whereas recent studies cast doubt on the correlation between intraprostatic testosterone lev‐ els and the carcinogenesis and progression of prostate cancer.82 Interestingly, the level of prostate‐specific antigen, a marker of pros‐ tate cancer, stays below the normal range regardless of the presence of TRT.83

6.2 | KS and diabetes

In the general population, a clear relationship between the serum testosterone concentration and insulin sensitivity has been re‐ ported.84,85 Low testosterone levels are associated with increased insulin resistance,86 and the onset of insulin resistance may be influ‐ enced by testosterone levels.87,88 Serum testosterone levels are in‐ dependently associated with insulin resistance, suggesting that low testosterone might be responsible for diabetes (in this review, type 2 diabetes),89 and a 5‐fold increase in metabolic syndrome38 has been observed in men with KS. After a diabetes diagnosis, atheroscle‐ rosis progressively follows, requiring the evaluation of endothelial function.

We expect and hope for a high efficacy of TRT on glucose me‐ tabolism. Some studies have reported that the actual treatment for low testosterone improves metabolic risk factors and insulin resis‐ tance in some individuals, but not all studies have shown positive results.90 Unfortunately, KS is a condition in which TRT does not have positive effects on glucose metabolism.91 In a study reported by Pasquali et al38 that included 48 men with KS and 21 men with hypogonadotropic hypogonadism who were all treated with TRT for 3 years, KS patients were more insulin resistant, had increased body fat and lower levels of HDL, and showed an increased prevalence of metabolic syndrome than those with hypogonadotropic hypogonad‐ ism treated with TRT. Compared to other types of hypogonadism, TRT has not been shown to improve metabolic syndrome or diabetes in KS patients,38,91 indicating either a potential hormonal resistance,

     |  147SHIRAISHI And MATSUYAMA

consistent with the accompanying elevated gonadotropins,80 an increased aromatization,92 or more simply, that testosterone is not involved in the glucose metabolism of KS, and more complex and un‐ revealed mechanisms exist that are associated with KS and glucose metabolism. However, information regarding the effect of TRT on glucose metabolism in Japanese men with KS is lacking, and investi‐ gations are needed to determine optimal therapeutic regimens and follow‐up schedules for Japanese patients.

6.3 | KS and cardiovascular disease

A number of reports indicate that KS is closely associated with CVD and abnormalities in electrocardiography and cardiopulmonary ex‐ ercise tests (reviewed in Salzano et al30). There are no standardized guidelines for the follow‐up of men with KS. In addition to the current guidelines of TRT for hypogonadism, including T, PSA, and hematocrit evaluation,93 KS patients should be followed up for related comor‐ bidities, especially for CVD. Because CVD is the most life‐threatening comorbidity, the initial evaluation has been proposed to include risk assessment for metabolic syndrome and thromboembolic disease as well as echocardiography.30 AS structural and functional cardiovas‐ cular abnormalities, a shorter QTc interval in KS patients compared with that in controls,94 and a 55% prevalence of mitral valve prolapse was found in 22 patients with KS. Data from large registry‐based studies95 indicate that men with KS are at an increased risk of throm‐ boembolic events. One reason for this increased risk is that the vis‐ cosity of blood in KS patients is high, causing the formation of venous thromboembolism.96 In addition, Campbell et al found that the risks of pulmonary embolism and deep venous thrombosis were 5‐20 times higher in KS patients than in normal healthy men.97 The updated AUA guideline for the evaluation and management of testosterone defi‐ ciency indicates that whether TRT increases or decreases the risk of cardiovascular events cannot be definitively stated. This guideline also indicates that there is no definitive evidence linking TRT to a higher incidence of venous thromboembolic events.98 Obviously, this guideline is for general hypogonadal men, and data on men with KS are needed for future investigations.

6.4 | KS and bone disease

Klinefelter syndrome patients also face an increased prevalence of bone disorders, particularly reduced BMD. A study found that 42.5% of KS patients had a combination of osteoporosis and os‐ teopenia, which was 8‐fold higher than the incidence in men with a normal karyotype.99 Reduced BMD is caused by increased bone turnover and is accompanied by an increased risk of bone frac‐ tures, especially in the femoral area. Unlike fractures that occur in aging males, men with KS are more active, and the influence of fractures on their body and socioeconomic aspects are more se‐ rious. Furthermore, decreased BMD and fractures affecting mor‐ bidity and mortality 68,95 have long been associated with KS. The mechanism of decreased BMD changes upon normal aging because the hypogonadism that occurs during the critical pubertal stages

of bone development accompanying low physical exercise capacity and muscle strength is present in KS patients. TRT has been shown to improve BMD,100 but vitamin D repletion has been demon‐ strated to be superior to TRT for improving BMD; KS patients are more prone to 25‐OH vitamin D fluctuations than normal men.99 Practically, biannual assessments of BMD and 25‐OH vitamin D levels to evaluate the risk of osteoporosis are recommended.80

6.5 | KS and immune diseases

The association between KS and immune diseases, including rheu‐ matoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic juvenile arthritis, psoriatic arthritis, polymyositis/dermatomyositis, systemic sclerosis, and mixed connective tissue disease, has long been described101,102; however, there has been no systematic evi‐ dence or rationale to account for the link. A retrospective study has demonstrated that compared to that of normal healthy men, men with KS have a significantly increased risk of developing Sjogren’s syndrome (risk ratio: 19.3), SLE (risk ratio: 18.1), Addison’s disease (risk ratio: 11.7), type 1 diabetes mellitus (risk ratio: 6.1), multiple sclerosis (risk ratio: 4.3), RA (risk ratio: 3.3), and acquired hypothy‐ roidism (risk ratio: 2.7) .

7   |   C O N C L U S I O N

The incidence of KS syndrome is 1:600, and the majority of patients in Japan are diagnosed upon a male infertility evaluation by medi‐ cal providers, especially gynecologists and urologists. Finding sperm via micro‐TESE is only one consideration for men with KS among a number of comorbidities that are found during adulthood, especially after infertility treatment. In other words, patients need lifelong care and often need a multidisciplinary team that includes general prac‐ titioners, psychologists, speech therapists, and endocrinologists in addition to urologists and gynecologists. Additionally, infertility specialists should understand the pathophysiology and previous his‐ tories of KS patients before they visit the IVF clinic, and discussions with general practitioners and pediatricians are sometimes needed to properly treat these patients. Again, KS should be managed from the infantile and pediatric periods to the geriatric period.

D I S C L O S U R E S

Conflict of interest: The authors declare no conflict of interest. Human rights statement and informed consent: This article does not contain any study with human participants that have been performed by any of the authors. Animal studies: This article does not contain any study with animal participants that have been performed by any of the authors.

O R C I D

Koji Shiraishi https://orcid.org/0000‐0002‐3278‐7747

148  |     SHIRAISHI And MATSUYAMA

R E F E R E N C E S

1. Klinefelter H, Albright F. Syndrome characterized by gynecomastia, aspermatogenesis without A‐Leydigism, and increased excretion of follicle stimulating hormone. J Clin Endocrinol. 1942;2:615‐627.

2. Higurashi M, Iijima K, Ishikawa N, Hoshina H, Watanabe N. Incidence of major chromosome aberrations in 12,319 newborn infants in Tokyo. Hum Genet. 1979;46:163‐172.

3. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab. 2003;88:622‐626.

4. Morris JK, Alberman E, Scott C, Jacobs P. Is the prevalence of Klinefelter syndrome increasing? Eur J Hum Genet. 2008;16:163‐170.

5. Forti G, Corona G, Vignozzi L, Krausz C, Maggi M. Klinefelter’s syn‐ drome: a clinical and therapeutical update. Sex Dev. 2010;4:249‐258.

6. Palermo GD, Schlegel PN, Sills ES, et al. Births after intracy‐ toplasmic injection of sperm obtained by testicular extraction from men with nonmosaic Klinefelter’s syndrome. N Engl J Med. 1998;338:588‐590.

7. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter’s syndrome. Lancet. 2004;364:273‐283.

8. Ramasamy R, Ricci JA, Palermo GD, Gosden LV, Rosenwaks Z, Schlegel PN. Successful fertility treatment for Klinefelter's syn‐ drome. J Urol. 2009;182:1108‐1113.

9. Takada S, Tsujimura A, Ueda T, et al. Androgen decline in patients with nonobstructive azoospemia after microdissection testicular sperm extraction. Urology. 2008;72:114‐118.

10. Tournaye H, Staessen C, Liebaers I, et al. Testicular sperm recovery in nine 47,XXY Klinefelter patients. XXY Klinefelter patients. Hum Reprod. 1996;11:1644‐1649.

11. Majzoub A, Arafa M, Al Said S, et al. Outcome of testicular sperm extraction in nonmosaic Klinefelter syndrome patients: what is the best approach? Andrologia. 2016;48:171‐176.

12. Corona G, Pizzocaro A, Lanfranco F, et al. Sperm recovery and ICSI outcomes in Klinefelter syndrome: a systematic review and meta‐ analysis. Hum Reprod Update. 2017;23:265‐275.

13. Maiburg MC, Hoppenbrouwers AC, van Stel HF, Giltay JC. Attitudes of Klinefelter men and their relatives toward TESE‐ICSI. J Assist Reprod Genet. 2011;28:809‐8014.

14. Okada H, Goda K, Yamamoto Y, et al. Age as a limiting factor for successful sperm retrieval in patients with nonmosaic Klinefelter’s syndrome. Fertil Steril. 2005;84:1662‐1664.

15. Aksglaede L, Juul A. Testicular function and fertility in men with Klinefelter syndrome: a review. Eur J Endocrinol. 2013;168:67‐76.

16. Franik S, Hoeijmakers Y, D'Hauwers K, et al. Klinefelter syndrome and fertility: sperm preservation should not be offered to children with Klinefelter syndrome. Hum Reprod. 2016;31:1952‐1959.

17. Gies I, Oates R, De Schepper J, Tournaye H. Testicular biopsy and cryopreservation for fertility preservation of prepubertal boys with Klinefelter syndrome: a pro/con debate. Fertil Steril. 2016;105:249‐255.

18. Rohayem J, Fricke R, Czeloth K, et al. Age and markers of Leydig cell function, but not of Sertoli cell function predict the success of sperm retrieval in adolescents and adults with Klinefelter’s syn‐ drome. Andrology. 2015;3:868‐875.

19. Cissen M, Meijerink AM, D'Hauwers KW, et al. Prediction model for obtaining spermatozoa with testicular sperm extraction in men with non‐obstructive azoospermia. Hum Reprod. 2016;31:1934‐1941.

20. Aksglaede L, Skakkebaek NE, Almstrup K, et al. Clinical and bio‐ logical parameters in 166 boys, adolescents and adults with non‐ mosaic Klinefelter syndrome: a Copenhagen experience. Acta Paediatr. 2011;100:793‐806.

21. Eliveld J, van Wely M, Meisner A, Repping S, van der Veen F, van Pelt A. The risk of TESE‐induced hypogonadism: a systematic re‐ view and meta‐analysis. Hum Reprod Update. 2018;24:442‐454.

22. Lahlou N, Fennoy I, Carel JC, Roger M. Inhibin B and anti‐Mullerian hormone, but not testosterone levels, are normal in infants with nonmosaic Klinefelter syndrome. J Clin Endocrinol Metab. 2004;89:1864‐1868.

23. Ross JL, Samango‐Sprouse C, Lahlou N, Kowal K, Elder FF, Zinn A. Early androgen deficiency in infants and young boys with 47,XXY Klinefelter Syndrome. Horm Res Paediatr. 2005;64:39‐45.

24. Aksglaede L, Petersen JH, Main KM, Skakkebaek NE, Juul A. High normal testosterone levels in infants with non‐mosaic Klinefelter’s syndrome. Eur J Endocrinol. 2007;57:345‐350.

25. Cabrol S, Ross JL, Fennoy I, Bouvattier C, Roger M, Lahlou N. Assessment of Leydig and Sertoli cell functions in infants with nonmosaic Klinefelter syndrome: insulin‐like peptide 3 levels are normal and positively correlated with LH levels. J Clin Endocrinol Metab. 2011;96:746‐753.

26. Boada R, Janusz J, Hutaff‐Lee C, Tartaglia N. The cognitive pheno‐ type in Klinefelter syndrome: a review of the literature including ge‐ netic and hormonal factors. Dev Disabil Res Rev. 2009;15:284‐294.

27. Geschwind DH, Boone KB, Miller BL, Swerdloff RS. Neurobehavioral phenotype of Klinefelter syndrome. Ment Retard Dev Disabil Res Rev. 2000;6:107‐116.

28. Simm PJ, Zacharin MR. The psychosocial impact of Klinefelter syn‐ drome–a 10 year review. J Pediatr Endocrinol Metab. 2006;19:499‐505.

29. Tartaglia N, Cordeiro L, Howell S, Wilson R, Janusz J. The spec‐ trum of the behavioral phenotype in boys and adolescents 47, XXY (Klinefelter syndrome). Pediatr Endocrinol Rev. 2010;8(Suppl. 1):151‐159.

30. Salzano A, Arcopinto M, Marra AM, et al. Klinefelter syndrome, cardiovascular system, and thromboembolic disease: review of lit‐ erature and clinical perspectives. Eur J Endocrinol. 2016;175:27‐40.

31. Rogol AD, Tartaglia N. Considerations for androgen therapy in chil‐ dren and adolescents with Klinefelter syndrome (47, XXY). Pediatr Endocrinol Rev. 2010;8(Suppl. 1):145‐150.

32. Davis SM, Cox‐Martin MG, Bardsley MZ, Kowal K, Zeitler PS, Ross JL. Effects of oxandrolone on cardiometabolic health in boys with klinefelter syndrome: a randomized controlled trial. J Clin Endocrinol Metab. 2017;102:176‐184.

33. Samango‐Sprouse C, Stapleton EJ, Lawson P, et al. Positive effects of early androgen therapy on the behavioral pheno‐ type of boys with 47, XXY. Am J Med Genet C Semin Med Genet. 2015;169:150‐157.

34. Mehta A, Clearman T, Paduch DA. Safety and efficacy of testos‐ terone replacement therapy in adolescents with Klinefelter syn‐ drome. J Urol. 2014;191(Suppl. 5):1527‐1531.

35. Tufik SB, Berro LF, Andersen ML, Tufik S. Re: safety and efficacy of testosterone replacement therapy in adolescents with klinefelter syndrome. J Urol. 2014;192(192):1300‐1301.

36. Martinez C, Suissa S, Rietbrock S, et al. Testosterone treatment and risk of venous thromboembolism: population based case‐con‐ trol study. BMJ. 2016;355; https://doi.org/10.1136/bmj.i5968.

37. Kübler A, Schulz G, Cordes U, Beyer J, Krause U. The influence of testosterone substitution on bone mineral density in pa‐ tients with Klinefelter's syndrome. Exp Clin Endocrinol Diabetes. 1992;100:129‐132.

38. Pasquali D, Arcopinto M, Renzullo A, et al. Cittadini, Cardiovascular abnormalities in Klinefelter syndrome. Int J Cardiol. 2013;168:754‐759.

39. Herlihy AS, McLachlan RI. Screening for Klinefelter syndrome. Curr Opin Endocrinol Diabetes Obes. 2015;22:224‐229.

40. Nieschlag E, Ferlin A, Gravholt CH, et al. The Klinefelter syn‐ drome: current management and research challenges. Andrology. 2016;4:545‐549.

41. Topper E, Dickerman Z, Prager‐Lewin R, Kaufman H, Maimon Z, Laron Z. Puberty in 24 patients with Klinefelter syndrome. Eur J Pediatr. 1982;139:8‐12.

     |  149SHIRAISHI And MATSUYAMA

42. Bonomi M, Rochira V, Pasquali D, et al. Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. J Endocrinol Investig. 2017;40:123‐134.

43. Forest MG, Lecoq A, Saez JM. Kinetics of human chorionic go‐ nadotropin‐induced steroidogenic response of the human testis. II. Plasma 17 alphahydroxyprogesterone, delta4‐androstenedione, estrone, and 17 beta‐estradiol: evidence for the action of human chorionic gonadotropin on intermediate enzymes implicated in steroid biosynthesis. J Clin Endocrinol Metab. 1979;49:284‐291.

44. Chang S, Skakkebaek A, Trolle C, et al. Anthropometry in Klinefelter syndrome—multifactorial influences due to CAG length, testos‐ terone treatment and possibly intrauterine hypogonadism. J Clin Endocrinol Metab. 2015;100:508‐517.

45. Høst C, Skakkebæk A, Groth KA, Bojesen A. The role of hypogo‐ nadism in Klinefelter syndrome. Asian J Androl. 2014;16:185‐191.

46. Aksglaede L, Wikstrom AM, Rajpert‐De Meyts E, Dunkel L, Skakkebaek NE, Juul A. Natural history of seminiferous tu‐ bule degeneration in Klinefelter syndrome. Hum Reprod Update. 2006;12:39‐48.

47. Wikström AM, Raivio T, Hadziselimovic F, et al. Klinefelter syndrome in adolescence: onset of puberty is associated with accelerated germ cell depletion. J Clin Endocrinol Metab. 2004;89:2263‐2270.

48. Davis SM, Rogol AD, Ross JL. Testis development and fertility po‐ tential in boys with Klinefelter syndrome. Endocrinol Metab Clin North Am. 2015;44:843‐865.

49. Lue Y, Rao PN, Sinha Hikim AP, et al. XXY male mice: an ex‐ perimental model for Klinefelter syndrome. Endocrinology. 2001;142:1461‐1470.

50. Paduch DA, Bolyakov A, Cohen P, Travis A. Reproduction in men with Klinefelter syndrome: the past, the present and the future. Semin Reprod Med. 2009;27:137‐148.

51. Skakkebaek NE. Two types of tubules containing only Sertoli cells in adults with Klinefelter's syndrome. Nature. 1969;223:643‐645.

52. Bergere M, Wainer R, Nataf V, et al. Biopsied testis cells of four 47, XXY patients: fluorescence in‐situ hybridization and ICSI results. Hum Reprod. 2002;17:32‐37.

53. Gies I, Schepper JD, Goossens E, Saen DV, Pennings G, Tournaye H. Spermatogonial stem cell preservation in boys with Klinefelter syndrome: to bank or not to bank, that’s the question. Fertil Steril. 2012;98:284‐289.

54. Gies I, de Schepper J, van Saen D, et al. Failure of a combined clini‐ cal‐ and hormonal‐based strategy to detect early spermatogenesis and retrieve spermatogonial stem cells in 47, XXY boys by single testicular biopsy. Hum Reprod. 2012;27:998‐1004.

55. Nahata L, Yu RN, Paltiel HJ, et al. Sperm retrieval in adolescents and young adults with klinefelter syndrome: a prospective. Pilot Study. J Pediatr. 2016;170:260‐265.

56. Damani MN, Mittal R, Oates RD. Testicular tissue extraction in a young male with 47, XXY Klinefelter’s syndrome: potential strat‐ egy for preservation of fertility. Fertil Steril. 2001;76:1054‐1056.

57. Rives N, Milazzo JP, Perdrix A, et al. The feasibility of fertility pres‐ ervation in adolescents with Klinefelter syndrome. Hum Reprod. 2013;28:1468‐1479.

58. Van Saen D, Tournaye H, Goossens E. Presence of spermatogonia in 47, XXY men with no spermatozoa recovered after testicular sperm extraction. Fertil Steril. 2012;97:319‐323.

59. Van Saen D, Gies I, De Schepper J, Tournaye H, Goossens E. Can pubertal boys with Klinefelter syndrome benefit from sper‐ matogonial stem cell banking? Hum Reprod. 2012;27:323‐330.

60. Mehta A, Bolyakov A, Roosma J, et al. Successful testicular sperm retrieval in adolescents with Klinefelter syndrome treated with at least 1 year of topical testosterone and aromatase inhibitor. Fertil Steril. 2013;100:970‐974.

61. Dabaja AA, Schlegel PN. Microdissection testicular sperm ex‐ traction: an update. Asian J Androl. 2013;15:35‐39.

62. Plotton I, Giscard d'Estaing S, Cuzin B, et al. Preliminary results of a prospective study of testicular sperm extraction in young versus adult patients with nonmosaic 47, XXY Klinefelter syndrome. J Clin Endocrinol Metab. 2015;100:961‐967.

63. Schiff JD, Palermo GD, Veeck LL, Goldstein M, Rosenwaks Z, Schlegel PN. Success of testicular sperm injection and intracyto‐ plasmic sperm injection in men with Klinefelter syndrome. J Clin Endocrinol Metab. 2005;90:6263‐6267.

64. Boivin J, Takefman J, Braverman A. The fertility quality of life (FertiQoL) tool: development and general psychometric proper‐ ties. Hum Reprod. 2011;26:2084‐2091.

65. Gies I, Tournaye H, De Schepper J. Attitudes of parents of Klinefelter boys and pediatricians towards neonatal screening and fertility preservation techniques in Klinefelter syndrome. Eur J Pediatr. 2016;175:399‐404.

66. Groth KA, Skakkebaek A, Host C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome—a clinical update. J Clin Endocrinol Metab. 2013;98:20‐30.

67. Wikstrom AM, Dunkel L. Klinefelter syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25:239‐250.

68. Bojesen A, Gravholt CH. Morbidity and mortality in Klinefelter syndrome (47, XXY). Acta Paediatr. 2011;100:807‐813.

69. Price WH, Clayton JF, Wilson J, Collyer S, DeMey R. Causes of death in X chromatin positive males (Klinefelter's syndrome). J Epidemiol Community Health. 1985;39:330‐336.

70. Muraleedharan V, Jones TH. Testosterone and mortality. Clin Endocrinol. 2014;81:477‐487.

71. Bojesen A, Gravholt CH. Klinefelter syndrome in clinical practice. Nat Clin Pract Urol. 2007;4:192‐204.

72. Nielsen J, Pelsen B, Sorensen K. Follow‐up of 30 Klinefelter males treated with testosterone. Clin Genet. 1988;33:262‐269.

73. Meikle AW, Dobs AS, Arver S, Caramelli KE, Sanders SW, Mazer NA. Androgen replacement in the treatment of Klinefelter’s syn‐ drome: efficacy and safety of a nonscrotal permeation‐enhanced testosterone transdermal system. Endocr Pract. 1998;4:17‐22.

74. Sasco AJ, Lowenfels AB, Pasker‐de JP. Review article: epidemiol‐ ogy of male breast cancer. A meta‐analysis of published case‐con‐ trol studies and discussion of selected aetiological factors. Int J Cancer. 1993;53:538‐549.

75. Brinton LA. Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatr. 2011;100:814‐818.

76. Gomez‐Raposo C, Zambrana Tevar F, Sereno Moyano M, Lopez Gomez M, Casado E. Male breast cancer. Cancer Treat Rev. 2010;36:451‐457.

77. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among pre‐ menopausal women. J Natl Cancer Inst. 2006;98:1406‐1415.

78. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678‐687.

79. De Sanctis V, Fiscina B, Soliman A, Giovannini M, Yassin M. Klinefelter syndrome and cancer: from childhood to adulthood. Pediatr Endocrinol Rev. 2013;11:44‐50.

80. Radicioni AF, Ferlin A, Balercia G, et al. Consensus statement on diagnosis and clinical management of Klinefelter syndrome. J Endocrinol Investig. 2010;33:839‐850.

81. Ji J, Zöller B, Sundquist J, Sundquist K. Risk of solid tumors and he‐ matological malignancy in persons with Turner and Klinefelter syn‐ dromes: a national cohort study. Int J Cancer. 2016;139:754‐758.

82. Debruyne F, Behre HM, Roehrborn CG, et al. Testosterone treat‐ ment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the registry of hypogonadism in men. BJU Int. 2017;119:216‐224.

83. Selice R, Mambro AD, Garolla A, et al. Testosterone, sex hor‐ mone‐binding globulin and the metabolic syndrome: a systematic

150  |     SHIRAISHI And MATSUYAMA

review and meta‐analysis of observational studies. Int J Epidemiol. 2011;40:189‐207.

84. Kelly DM, Akhtar S, Sellers DJ, Muraleedharan V, Channer KS, Jones TH. Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the tes‐ ticular feminised mouse. Endocrine. 2016;54:504‐515.

85. Mitsuhashi K, Senmaru T, Fukuda T, et al. Testosterone stimulates glucose uptake and GLUT4 translocation through LKB1/AMPK sig‐ naling in 3T3‐L1 adipocytes. Endocrine. 2016;51:174‐184.

86. Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age‐associated changes in hypothalamic‐pituitary‐testicular function in middle‐ aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013;168:445‐455.

87. Landry D, Pare A, Jean S, Martin LJ. Adiponectin influences pro‐ gesterone production from MA‐10 Leydig cells in a dose‐depen‐ dent manner. Endocrine. 2015;48:957‐967.

88. Yesilova Z, Oktenli C, Sanisoglu SY, et al. Evaluation of insulin sen‐ sitivity in patients with Klinefelter’s syndrome: a hyperinsulinemic euglycemic clamp study. Endocrine. 2005;27:11‐15.

89. Isidori AM, Balercia G, Calogero AE, et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommenda‐ tions from the Italian society of endocrinology. J Endocrinol Invest. 2015;38:103‐112.

90. Bojesen A, Kristensen K, Birkebaek NH, et al. The metabolic syndrome is frequent in Klinefelter's syndrome and is associ‐ ated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29:1591‐1598.

91. Bekaert M, Van Nieuwenhove Y, Calders P, et al. Determinants of testosterone levels in human male obesity. Endocrine. 2015;50:202‐211.

92. Cunningham GR, Stephens‐Shields AJ, Rosen RC, et al. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab. 2016;101:3096‐3104.

93. Jorgensen IN, Skakkebaek A, Andersen NH, et al. Short QTc in‐ terval in males with klinefelter syndrome‐influence of CAG repeat length, body composition, and testosterone replacement therapy. Pacing Clin Electrophysiol. 2015;38:472‐482.

94. Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA; United Kingdom Clinical Cytogenetics Group. Mortality in pa‐ tients with Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab. 2005;90:6516‐6522.

95. Zoller B, Ji J, Sundquist J, Sundquist K. High risk of venous thromboembolism in Klinefelter syndrome. J Am Heart Assoc. 2016;5:e003567.

96. Campbell WA, Price WH. Venous thromboembolic disease in Klinefelter’s syndrome. Clin Genet. 1981;19:275‐280.

97. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and man‐ agement of testosterone deficiency: AUA guideline. J Urol. 2018;200:423‐432.

98. Ferlin A, Selice R, Di Mambro A, et al. Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome. Osteoporos Int. 2015;26:2193‐2202.

99. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Longterm effect of testosterone therapy on bone mineral density in hypogo‐ nadal men. J Clin Endocrinol Metab. 1997;82:2386‐2390.

100. Sawalha AH, Harley JB, Scofield RH. Autoimmunity and Klinefelter's syndrome: when men have two X chromosomes. J Autoimmun. 2009;33:31‐34.

101. Rovenský J, Imrich R, Lazúrová I, Payer J. Rheumatic diseases and Klinefelter's syndrome: annals of the New York Academy of Sciences. Ann N Y Acad Sci. 2010;1193:1‐9.

102. Seminog OO, Seminog AB, Yeates D, Goldacre MJ. Associations between Klinefelter's syndrome and autoimmune diseases: English national record linkage studies. Autoimmunity. 2015;48:125‐128.

103. Nichols CR, Heerema NA, Palmer C, et al. Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 1987;5:1290‐1294.

104. Aksglaede L, Skakkebaek NE, Juul A. Abnormal sex chromosome constitution and longitudinal growth: serum levels of insulin‐like growth factor (IGF)‐I, IGF binding protein‐3, luteinizing hormone, and testosterone in 109 males with 47, XXY, 47, XYY, or sex‐deter‐ mining region of the Y chromosome (SRY)‐positive 46, XX karyo‐ types. J Clin Endocrinol Metab. 2008;93:169‐176.

105. Laaksonen DE, Niskanen L, Punnonen K, et al. Estosterone and sex hormone‐binding globulin predict he metabolic syndrome and diabetes in middle‐aged men. Diabetes Care. 2014;27:1036‐1041.

106. Takeuchi Y, Murata Y, Sintani J, et al. Klinefelter's syndrome ac‐ companied by mixed connective tissue disease and diabetes melli‐ tus. Intern Med. 1999;38:875‐881.

107. Lichiardopol C, Mota M, Pănuş C. Metabolic changes in Klinefelter syndrome. Rom J Intern Med. 2004;42:415‐422.

108. Fricke GR, Mattern HJ, Schweikert HU. Mitral valve prolapse in Klinefelter syndrome. Lancet. 1981;2:8260‐8261.

109. Fricke GR, Mattern HJ, Schweikert HU, et al. Klinefelter's syn‐ drome and mitral valve prolapse. an echocardiographic study in twenty‐two patients. Biomed Pharmacother. 1984;38:88‐97.

110. Liu T, Shehata M, Li G, Wang X. Androgens and atrial fibrillation: friends or foes? Int J Cardiol. 2010;145:365‐367.

111. Lai J, Zhou D, Xia S, et al. Reduced testosterone levels in males with lone atrial fibrillation. Clin Cardiol. 2009;2:43‐46.

112. Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene‐dose effect from the X chromosome. Arthritis Rheum. 2008;58:2511‐2517.

113. El‐Mansoury M, Bryman I, Berntorp K, et al. Hypothyroidism is common in Turner syndrome: results of a five‐year follow‐up. J Clin Endocrinol Metab. 2005;90:2131‐2135.

How to cite this article: Shiraishi K, Matsuyama H. Klinefelter syndrome: From pediatrics to geriatrics. Reprod Med Biol. 2019;18:140–150. https://doi.org/10.1002/rmb2.12261

Copyright of Reproductive Medicine & Biology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.